Semin Thromb Hemost 2000; Volume 26(Number s1): 085-086
DOI: 10.1055/s-2000-9245
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Antithrombotics and Anticoagulants in Coronary Syndromes and Stroke

Alexander G.G. Turpie
  • Hamilton Health Sciences Corporation, General Division, Hamilton, Ontario, Canada
Further Information

Publication History

Publication Date:
31 December 2000 (online)

 

ABSTRACT

The low-molecular-weight heparins (LMWHs) have been proven superior to placebo in reducing the incidence of acute coronary ischemic syndromes. Comparative studies vs. unfractionated heparin have not demonstrated superiority in favor of the LMWH dalteparin. In the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) trial, enoxaparin was demonstrated to have a benefit over heparin. The results have contributed to a better understanding of the relative efficacy of LMWHs in acute coronary syndromes. A second trial with enoxaparin supported the conclusions of the ESSENCE trial.

The antithrombotic effects of LMWHs have also been evaluated for the management of ischemic stroke with varied results. A trial assessing tinzaparin in acute ischemic stroke has completed enrollment, and its results may shed new light on the use of an LMWH for the management of stroke.

KEYWORD

Low-molecular-weight heparin - acute ischemic syndrome - stroke

REFERENCES

  • 1 Yeghiazarians Y, Braunstein J B, Askari A, Stone P H. Medical progress: Unstable angina pectoris.  N Engl J Med . 2000;  342 101-114
    CrossrefPubMedSearch in Google Scholar
  • 2 Opinions regarding the diagnosis and management of venous thromboembolic disease. ACCP Consensus Committee on Pulmonary Embolism.  Chest. 1998;  113 499-504
    PubMedSearch in Google Scholar
  • 3 Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.  Br Med J. 1994;  308 81-106
    PubMedSearch in Google Scholar
  • 4 Turpie A G. Anticoagulants in acute coronary syndromes.  Am J Cardiol . 1999;  84 2M-6M
    PubMedSearch in Google Scholar
  • 5 Balsano F, Rizzon P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group.  Circulation . 1990;  82 17-26
    PubMedSearch in Google Scholar
  • 6 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet . 1996;  348 1329-1339
    CrossrefPubMedSearch in Google Scholar
  • 7 Théroux P, Waters D, Qiu S. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.  Circulation . 1993;  88(5 pt 1) 2045-2048
    PubMedSearch in Google Scholar
  • 8 Turpie A G. Clinical potential of antithrombotic drugs in coronary syndromes.  Am J Cardiol . 1998;  82 11L-14L
    CrossrefPubMedSearch in Google Scholar
  • 9 Théroux P, Ouimet H, McCans J. Aspirin, heparin, or both to treat acute unstable angina.  N Engl J Med . 1988;  319 1105-1111
    CrossrefPubMedSearch in Google Scholar
  • 10 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.  Lancet . 1990;  336 827-830
    CrossrefPubMedSearch in Google Scholar
  • 11 Cohen M, Adams P C, Parry G. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.  Circulation . 1994;  89 81-88
    PubMedSearch in Google Scholar
  • 12 Gurfinkel E, Fareed J, Antman E, Cohen M, Mautner B. Rationale for the management of coronary syndromes with low-molecular-weight heparins.  Am J Cardiol . 1998;  82 15L-18L
    CrossrefPubMedSearch in Google Scholar
  • 13 FRagmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease.  Lancet . 1996;  347 561-568
    CrossrefPubMedSearch in Google Scholar
  • 14 Wallentin L, Husted S, Kontny F, Swahn E. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).  Am J Cardiol . 1997;  80 61E-63E
    CrossrefPubMedSearch in Google Scholar
  • 15 Klein W, Buchwald A, Hillis S E. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study.  Circulation . 1997;  96 61-68
    PubMedSearch in Google Scholar
  • 16 Cohen M, Demers C, Gurfinkel E P. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.  N Engl J Med . 1997;  337 447-452
    CrossrefPubMedSearch in Google Scholar
  • 17 Goodman S, Bigonzi F, Radley D, LeIouer V, Gosset F, Cohen M. One-year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction).  Eur Heart J. 1998;  50 (50 (Abstr))
    PubMedSearch in Google Scholar
  • 18 The FRAX.I.S. Study Group.. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).  Eur Heart J . 1999;  20 1553-1562
    CrossrefPubMedSearch in Google Scholar
  • 19 FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study.  Lancet . 1999;  354 708-715
    CrossrefPubMedSearch in Google Scholar
  • 20 Antman E M, McCabe C H, Gurfinkel E P. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial.  Circulation . 1999;  100 1593-1601
    PubMedSearch in Google Scholar
  • 21 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke.  Lancet . 1997;  349 1569-1581
    CrossrefPubMedSearch in Google Scholar
  • 22 CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke.  Lancet . 1997;  349 1641-1649
    CrossrefPubMedSearch in Google Scholar
  • 23 Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.  JAMA. 1998;  279 1265-1272
    CrossrefPubMedSearch in Google Scholar
  • 24 Kay R, Wong K S, Yu Y L. Low-molecular-weight heparin for the treatment of acute ischemic stroke.  N Engl J Med . 1995;  333 1588-1593
    CrossrefPubMedSearch in Google Scholar
  • 25 Hommel M, FISS bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis).  Cerebrovasc Dis. 1998;  8 ((Suppl 4) (Abstr)) 1-103
    PubMedSearch in Google Scholar